Janssen Owes Family $10M In Topamax Suit, Jury Says

Law360, Los Angeles (November 18, 2013, 9:45 PM EST) -- A Philadelphia state jury decided on Monday that Janssen Pharmaceuticals Inc. is obligated to pay more than $10 million to the parents of a child who allegedly suffered birth defects due to the company's epilepsy drug Topamax, according to attorneys for the family.

The jury determined that the Johnson & Johnson unit didn't sufficiently warn doctors about the risk of birth defects stemming from the use of the drug, plaintiffs' counsel said. The company allegedly knew about the risks years before the drug was prescribed to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.